AR071285A1 - Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos. - Google Patents
Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos.Info
- Publication number
- AR071285A1 AR071285A1 ARP090101069A ARP090101069A AR071285A1 AR 071285 A1 AR071285 A1 AR 071285A1 AR P090101069 A ARP090101069 A AR P090101069A AR P090101069 A ARP090101069 A AR P090101069A AR 071285 A1 AR071285 A1 AR 071285A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- independently
- alkyl
- unit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos heterocíclicos que se pueden usar para modular un receptor de histamina en un individuo. Se describen compuestos derivados de pirido[4,3-b]indoles. También se proveen composiciones farmacéuticas. Reivindicacion 1: Un compuesto caracterizado porque es de la formula (1): en donde: R1 es H, hidroxilo, nitro, ciano, halo, alquilo C1-8 sustituido o no sustituido, alquenilo C2-8 sustituido o no sustituido, alquinilo C2-8 sustituido o no sustituido, perhaloalquilo, acilo, aciloxi, carbonilalcoxi, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, aralquilo sustituido o no sustituido, perhaloalcoxi C1-8, alcoxi, ariloxi, carboxilo, tiol, tioalquilo, amino sustituido o no sustituido, acilamino, aminoacilo, aminocarbonilamino, aminocarboniloxi, aminosulfonilo, sulfonilamino, sulfonilo o carbonilalquilenalcoxi; cada R2a y R2b es en forma independiente H, alquilo C1-8 sustituido o no sustituido, halo, ciano, hidroxilo, alcoxi o nitro, o R2a y R2b se toman junto con el carbono al cual están unidos para formar una unidad cicloalquilo o una unidad carbonilo; cada R3a y R3b es en forma independiente H, alquilo C1-8 sustituido o no sustituido, halo, ciano, nitro, hidroxilo, alcoxi, amino, amino sustituido, cicloalquilo, fenilo, acilamino o aciloxi, o R3 y R3b se toman junto con el carbono al cual están unidos para formar una unidad cicloalquilo o una unidad carbonilo; cada X7, X8, X9 y X10 es en forma independiente N o CR4; m y q son en forma independiente 0 o 1; cada R4 es en forma independiente H, hidroxilo, nitro, ciano, halo, perhaloalquilo C1-8, alquilo C1-8 sustituido o no sustituido, alquenilo C2-8 sustituido o no sustituido, alquinilo C2-8 sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, perhaloalcoxi C1-8, alcoxi C1-8, ariloxi, carboxilo, tiol, carbonilalcoxi, heterociclilo sustituido o no sustituido, aralquilo sustituido o no sustituido, tioalquilo, amino sustituido o no sustituido, acilamino, aminoacilo, aminocarbonilamino, aminocarboniloxi, aminosulfonilo, sulfonilamino, sulfonilo, carbonilalquilenalcoxi, alquilsulfonilamino o acilo; cada R8a, R8b, R8c y R8d es en forma independiente H, hidroxilo, alquilo C1-8, perhaloalquilo C1-8, carboxi, carbonilalcoxi, se toma junto con el carbono al cual está unido y un R8 geminal (a-d) para formar una unidad cicloalquilo o una unidad carbonilo, o se toma junto con un R8 geminal (a-d) para formar un metileno o un metileno sustituido; cada R10a y R10b es en forma independiente H, halo, alquilo C1-8 sustituido o no sustituido, hidroxilo, alcoxilo, ciano o nitro, o R10a y R10b toman junto con el carbono al cual están unidos para formar una unidad cicloalquilo o una unidad carbonilo; R11 y R12 son en forma independiente H o alquilo C1-8, perhaloalquilo C1-8, carboxi, carbonilalcoxi, o se toman junto con y los átomos de carbono a los cuales están unidos para formar una unidad cicloalquilo C3-8 sustituido o no sustituido, cicloalquenilo C3-8 sustituido o no sustituido o heterociclilo sustituido o no sustituido o se toman juntos para formar un enlace, formando así una unidad acetilenilo; indica la presencia de una configuracion de doble enlace E o Z cuando R11 y R12 son en forma independiente H, alquilo C1-8, perhaloalquilo C1-8, carboxi o carbonilalcoxi; y Q es un arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, amino no sustituido, amino sustituido, alcoxi, aminoacilo, aciloxi, carbonilalcoxi, aminocarbonilalcoxi, acilamino, carboxi, ciano o alquinilo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3905608P | 2008-03-24 | 2008-03-24 | |
| US14507909P | 2009-01-15 | 2009-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071285A1 true AR071285A1 (es) | 2010-06-09 |
Family
ID=40810809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101069A AR071285A1 (es) | 2008-03-24 | 2009-03-25 | Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8338447B2 (es) |
| EP (1) | EP2280968A2 (es) |
| JP (2) | JP5679538B2 (es) |
| CN (2) | CN102083830B (es) |
| AR (1) | AR071285A1 (es) |
| AU (1) | AU2009228398B2 (es) |
| BR (1) | BRPI0906244A2 (es) |
| CA (1) | CA2719412A1 (es) |
| CL (1) | CL2009000724A1 (es) |
| HK (1) | HK1158636A1 (es) |
| PE (1) | PE20091717A1 (es) |
| TW (1) | TWI443098B (es) |
| WO (1) | WO2009120717A2 (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2683453C (en) * | 2007-04-05 | 2013-06-11 | Alla Chem, Llc | Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) * | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| PE20091717A1 (es) | 2008-03-24 | 2009-11-25 | Medivation Technologies Inc | Pirido[3,4-b] indoles como moduladores de receptores de histamina |
| BRPI0906245A2 (pt) | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit |
| CN102227431A (zh) | 2008-09-29 | 2011-10-26 | 雅培制药有限公司 | 吲哚和二氢吲哚衍生物及其应用方法 |
| US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
| TWI482773B (zh) * | 2008-10-31 | 2015-05-01 | Medivation Technologies Inc | 氮呯并〔４，５－ｂ〕吲哚及使用方法 |
| TWI477503B (zh) | 2008-10-31 | 2015-03-21 | Medivation Technologies Inc | 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚 |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2385829B1 (en) | 2009-01-09 | 2018-08-01 | Board of Regents of the University of Texas System | Pro-neurogenic compounds |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| RU2011137419A (ru) | 2009-02-11 | 2013-03-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты гистамина н3 и способы их применения |
| CN102480955B (zh) | 2009-04-29 | 2015-08-05 | 梅迪维新技术公司 | 吡啶并[4,3-b]吲哚类和使用方法 |
| US8741919B2 (en) | 2009-04-29 | 2014-06-03 | Medivation Technologies, Inc. | Pyrido[4,3-B]indoles and methods of use |
| AU2010292285A1 (en) * | 2009-09-11 | 2012-03-15 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| AU2010298166B2 (en) | 2009-09-23 | 2015-09-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| US9079904B2 (en) * | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| AU2010298169B2 (en) | 2009-09-23 | 2015-10-29 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
| WO2011038162A1 (en) * | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
| FR2953836B1 (fr) * | 2009-12-14 | 2012-03-16 | Sanofi Aventis | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103487A1 (en) * | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| EP2590647B1 (en) | 2010-07-07 | 2017-11-08 | Board of Regents of the University of Texas System | Pro-neurogenic compounds |
| US9199985B2 (en) | 2011-02-18 | 2015-12-01 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| JP2014505738A (ja) | 2011-02-18 | 2014-03-06 | メディベイション テクノロジーズ， インコーポレイテッド | 高血圧を処置するための化合物および方法 |
| WO2012112964A2 (en) * | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| SG192853A1 (en) * | 2011-02-21 | 2013-09-30 | Taisho Pharmaceutical Co Ltd | Glycine transporter-inhibiting substances |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| WO2014031165A1 (en) * | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| EP2887803A4 (en) | 2012-08-24 | 2016-08-03 | Univ Texas | PRO-NEUROGENIC COMPOUNDS |
| US10394936B2 (en) * | 2012-11-06 | 2019-08-27 | International Business Machines Corporation | Viewing hierarchical document summaries using tag clouds |
| EP3068388A4 (en) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Neuroprotective compounds and use thereof |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| CN113164508A (zh) | 2018-12-19 | 2021-07-23 | 达萨玛治疗公司 | 与神经保护剂组合的sarm1抑制剂 |
| KR20210134689A (ko) | 2019-02-27 | 2021-11-10 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| KR20210134928A (ko) | 2019-02-27 | 2021-11-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 n-치환된 인돌 및 다른 헤테로사이클 |
| IL295677A (en) | 2020-02-24 | 2022-10-01 | Gilead Sciences Inc | Tetracyclic compounds for treating hiv infection |
| KR20230066311A (ko) * | 2020-06-10 | 2023-05-15 | 델릭스 테라퓨틱스, 인크. | 삼환형 사이코플라스토겐 및 이의 용도 |
| KR20230134529A (ko) | 2021-01-19 | 2023-09-21 | 길리애드 사이언시즈, 인코포레이티드 | 치환된 피리도트리아진 화합물 및 이의 용도 |
| CN114539250B (zh) * | 2022-03-04 | 2023-08-29 | 上海裕兰生物科技有限公司 | 一种阿尔兹海默症PET-tau示踪剂的制备方法 |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| CN116751197B (zh) * | 2023-03-27 | 2024-04-12 | 中国科学院昆明植物研究所 | 卡波林生物碱或其药学上可接受的盐及其制备方法和应用、卡波林生物碱药物组合物及应用 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2642438A (en) | 1949-07-15 | 1953-06-16 | Hoffmann La Roche | Pyridindoles and method of manufacture |
| GB721171A (en) * | 1951-04-30 | 1954-12-29 | Bayer Ag | Derivatives of ª‰- and ª†- carbolines |
| JPS3920857B1 (es) | 1962-05-17 | 1964-09-24 | ||
| JPS412713B1 (es) | 1963-08-30 | 1966-02-21 | ||
| DE3240511A1 (de) | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur herstellung von ss-carbolinderivaten |
| US4754038A (en) | 1987-02-26 | 1988-06-28 | American Home Products Corporation | Carboline histamine H1 antagonists |
| US5817756A (en) | 1993-09-09 | 1998-10-06 | Scios Inc. | Pseudo- and non-peptide bradykinin receptor antagonists |
| ES2148347T3 (es) | 1993-09-09 | 2000-10-16 | Scios Inc | Antagonistas del receptor de la bradiquinina pseudo y no peptidica. |
| US5631265A (en) | 1994-03-11 | 1997-05-20 | Eli Lilly And Company | 8-substituted tetrahydro-beta-carbolines |
| US5688807A (en) | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
| AU679635B2 (en) | 1994-03-11 | 1997-07-03 | Eli Lilly And Company | Method for treating 5HT-2B receptor related conditions |
| JPH11505217A (ja) | 1995-05-05 | 1999-05-18 | ノボ ノルディスク アクティーゼルスカブ | 新規複素環の化学 |
| RU2140417C1 (ru) | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
| GB9604996D0 (en) | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
| TR199801970T2 (xx) | 1996-04-04 | 2000-10-23 | F.Hoffmann-La Roche Ag | Tetrahidro-beta-karbolinlerin antimetastatik ajanlar olarak kullan�m�. |
| AU1407399A (en) | 1997-11-14 | 1999-06-07 | Eli Lilly And Company | Treatment for alzheimer's disease |
| FR2771095B1 (fr) | 1997-11-14 | 1999-12-17 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2316388C (en) | 1997-12-25 | 2009-09-08 | Meiji Seika Kaisha Ltd. | Tetrahydrobenzindole derivative |
| FR2796644B1 (fr) | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| UA74826C2 (en) | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
| EP1633751A1 (en) | 2003-06-16 | 2006-03-15 | Chroma Therapeutics Limited | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
| JP4671123B2 (ja) | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
| US20070134733A1 (en) | 2003-07-10 | 2007-06-14 | Parallax Biosystems, Inc. | Raman signature probes and their use in the detection and imaging of molecular processes and structures |
| US20070179174A1 (en) | 2003-12-08 | 2007-08-02 | Bachurin Sergei O | Methods and compositions for slowing aging |
| RU2283108C2 (ru) | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| JP4734119B2 (ja) | 2004-02-12 | 2011-07-27 | 田辺三菱製薬株式会社 | インダゾール化合物及びその医薬用途 |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| WO2006011750A1 (en) | 2004-07-27 | 2006-02-02 | C & C Research Laboratories | Tetrahydro-beta-carbolinone derivatives and process for preparing the same |
| JP2008530136A (ja) | 2005-02-14 | 2008-08-07 | ミイカナ セラピューティクス インコーポレイテッド | ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物 |
| US20090029979A1 (en) * | 2005-07-07 | 2009-01-29 | Bio-Medisinsk Innovasjon As | 5-htx modulators |
| EP1747779A1 (en) | 2005-07-28 | 2007-01-31 | Laboratorios Del Dr. Esteve, S.A. | Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands |
| CA2624731A1 (en) | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington's disease |
| RU2338537C2 (ru) | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| EP1991228A1 (en) * | 2006-02-28 | 2008-11-19 | Boehringer Ingelheim International GmbH | Treatment of prevention of valvular heart disease with flibanserin |
| EP2063892A2 (en) | 2006-09-20 | 2009-06-03 | Medivation Neurology, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis (als) |
| AU2007297618A1 (en) | 2006-09-20 | 2008-03-27 | Medivation Neurology, Inc. | Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine Cognitive Dysfunction Syndrome |
| SG178000A1 (en) | 2006-10-27 | 2012-02-28 | Medivation Neurology Inc | Methods and combination therapies for treating alzheimer's disease |
| RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| RU2334514C1 (ru) | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2340342C2 (ru) | 2006-12-07 | 2008-12-10 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| CN101627013A (zh) | 2007-02-07 | 2010-01-13 | 安斯泰来制药有限公司 | 酰基胍衍生物 |
| DE102007009264A1 (de) | 2007-02-26 | 2008-08-28 | Ellneuroxx Ltd. | 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen |
| RU2338745C1 (ru) | 2007-03-21 | 2008-11-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| RU2339637C1 (ru) | 2007-04-05 | 2008-11-27 | Андрей Александрович Иващенко | Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием |
| CA2683453C (en) | 2007-04-05 | 2013-06-11 | Alla Chem, Llc | Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof |
| MX2009012788A (es) | 2007-05-25 | 2010-01-14 | Medivation Neurology Inc | Metodos y composiciones para estimular celulas. |
| RU2338533C1 (ru) | 2007-06-28 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| CA2719824A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| WO2009039420A1 (en) | 2007-09-21 | 2009-03-26 | Medivation Neurology, Inc. | Methods and compositions for treating neuronal death mediated ocular diseases |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| EP2179999A4 (en) | 2007-12-18 | 2011-06-08 | Univ Toyama Nat Univ Corp | CONDENSED TRICYCLIC COMPOUND WITH ALDOSIS REDUCTASE HARMFUL EFFECT |
| JP2011507835A (ja) | 2007-12-21 | 2011-03-10 | アンドレイ・アレクサンドロビッチ・イワシェンコ | α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用 |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2009111540A1 (en) | 2008-03-04 | 2009-09-11 | Medivation Neurology, Inc. | Methods for preparing pyridylethyl-substituted carbolines |
| ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
| PE20091717A1 (es) | 2008-03-24 | 2009-11-25 | Medivation Technologies Inc | Pirido[3,4-b] indoles como moduladores de receptores de histamina |
| BRPI0906245A2 (pt) | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit |
| CA2719742C (en) | 2008-03-27 | 2016-11-08 | Gruenenthal Gmbh | Substituted spirocyclic cyclohexane derivatives |
| WO2009135091A1 (en) | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| UY31832A (es) | 2008-05-20 | 2010-01-05 | Astrazeneca Ab | Derivados de indazol sustituidos con fenilo y benzodioxinilo |
| US20100029706A1 (en) | 2008-07-30 | 2010-02-04 | Edison Parmaceuticals, Inc. a Delaware Corporation | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS |
| TWI482773B (zh) | 2008-10-31 | 2015-05-01 | Medivation Technologies Inc | 氮呯并〔４，５－ｂ〕吲哚及使用方法 |
| TWI477503B (zh) | 2008-10-31 | 2015-03-21 | Medivation Technologies Inc | 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚 |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2385829B1 (en) | 2009-01-09 | 2018-08-01 | Board of Regents of the University of Texas System | Pro-neurogenic compounds |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| US8741919B2 (en) | 2009-04-29 | 2014-06-03 | Medivation Technologies, Inc. | Pyrido[4,3-B]indoles and methods of use |
| CN102480955B (zh) | 2009-04-29 | 2015-08-05 | 梅迪维新技术公司 | 吡啶并[4,3-b]吲哚类和使用方法 |
| WO2011014695A1 (en) | 2009-07-29 | 2011-02-03 | Medivation Technologies, Inc. | New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use |
| US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| AU2010298169B2 (en) | 2009-09-23 | 2015-10-29 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
| WO2011038162A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
| AU2010298166B2 (en) | 2009-09-23 | 2015-09-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103487A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103448A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Methods and compositions for treating psychotic disorders using antipsychotic combination therapy |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| EP2590647B1 (en) | 2010-07-07 | 2017-11-08 | Board of Regents of the University of Texas System | Pro-neurogenic compounds |
| JP2014505738A (ja) | 2011-02-18 | 2014-03-06 | メディベイション テクノロジーズ， インコーポレイテッド | 高血圧を処置するための化合物および方法 |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| US9199985B2 (en) | 2011-02-18 | 2015-12-01 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2014031165A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| AU2012388221B2 (en) | 2012-08-24 | 2017-08-31 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
-
2009
- 2009-03-24 PE PE2009000435A patent/PE20091717A1/es not_active Application Discontinuation
- 2009-03-24 CN CN200980118779.4A patent/CN102083830B/zh not_active Expired - Fee Related
- 2009-03-24 JP JP2011501989A patent/JP5679538B2/ja not_active Expired - Fee Related
- 2009-03-24 EP EP09725186A patent/EP2280968A2/en not_active Withdrawn
- 2009-03-24 CA CA2719412A patent/CA2719412A1/en not_active Abandoned
- 2009-03-24 CL CL2009000724A patent/CL2009000724A1/es unknown
- 2009-03-24 AU AU2009228398A patent/AU2009228398B2/en not_active Ceased
- 2009-03-24 CN CN201410535056.7A patent/CN104387382A/zh active Pending
- 2009-03-24 US US12/410,407 patent/US8338447B2/en not_active Expired - Fee Related
- 2009-03-24 BR BRPI0906244-0A patent/BRPI0906244A2/pt not_active IP Right Cessation
- 2009-03-24 WO PCT/US2009/038138 patent/WO2009120717A2/en active Application Filing
- 2009-03-24 TW TW098109572A patent/TWI443098B/zh not_active IP Right Cessation
- 2009-03-25 AR ARP090101069A patent/AR071285A1/es unknown
-
2011
- 2011-11-30 HK HK11112991.1A patent/HK1158636A1/xx not_active IP Right Cessation
-
2012
- 2012-11-16 US US13/679,883 patent/US9469641B2/en not_active Expired - Fee Related
- 2012-12-21 US US13/725,937 patent/US9260429B2/en not_active Expired - Fee Related
-
2013
- 2013-03-08 US US13/791,781 patent/US20130190323A1/en not_active Abandoned
- 2013-03-08 US US13/791,677 patent/US20130184306A1/en not_active Abandoned
- 2013-12-12 JP JP2013256618A patent/JP5748240B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009228398B2 (en) | 2014-07-03 |
| AU2009228398A1 (en) | 2009-10-01 |
| US9260429B2 (en) | 2016-02-16 |
| TW201000478A (en) | 2010-01-01 |
| US20130190323A1 (en) | 2013-07-25 |
| EP2280968A2 (en) | 2011-02-09 |
| CN102083830B (zh) | 2014-11-12 |
| US20090270412A1 (en) | 2009-10-29 |
| CA2719412A1 (en) | 2009-10-01 |
| JP5679538B2 (ja) | 2015-03-04 |
| US20130079352A1 (en) | 2013-03-28 |
| WO2009120717A2 (en) | 2009-10-01 |
| JP2011515482A (ja) | 2011-05-19 |
| CN104387382A (zh) | 2015-03-04 |
| US20130184306A1 (en) | 2013-07-18 |
| US8338447B2 (en) | 2012-12-25 |
| CN102083830A (zh) | 2011-06-01 |
| JP5748240B2 (ja) | 2015-07-15 |
| US20130131077A1 (en) | 2013-05-23 |
| WO2009120717A3 (en) | 2009-12-03 |
| US9469641B2 (en) | 2016-10-18 |
| HK1158636A1 (en) | 2012-07-20 |
| BRPI0906244A2 (pt) | 2015-06-30 |
| CL2009000724A1 (es) | 2009-05-29 |
| TWI443098B (zh) | 2014-07-01 |
| PE20091717A1 (es) | 2009-11-25 |
| JP2014051526A (ja) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071285A1 (es) | Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos. | |
| AR072042A1 (es) | Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos | |
| AR071284A1 (es) | Compuestos heterociclicos con uniones puente y metodos para usarlos | |
| AR073923A1 (es) | Pirido( 4,3-b) indoles que contienen restos rigidos | |
| MX2013007104A (es) | Derivados de biciclo[3,2,1]octilamida y sus usos. | |
| HK1165954A1 (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| NO20080391L (no) | Pyrazolbaserte LXR modulatorer | |
| MY151983A (en) | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators | |
| AR073924A1 (es) | Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina. | |
| AR080974A1 (es) | Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras. | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| CO6541645A2 (es) | Compuestos de indol y su uso farmaceutico | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| ATE493404T1 (de) | Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren | |
| MX2011007737A (es) | Derivados de hidroximetil isoxazol como moduladores de acido gamma-aminobutirico a. | |
| UY29798A1 (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| AR083017A1 (es) | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol | |
| UA107473C2 (uk) | Конденсовані тіазоло- та оксазолопіримідинони | |
| IL206611A0 (en) | Novel imidazolinylmethyl aryl sulfonamides | |
| CL2012000102A1 (es) | Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras. | |
| MX2010007928A (es) | Imidazolinilmetil aril sulfonamidas novedosas. | |
| BRPI0907495A2 (pt) | sulfonamidas de imidazolinilmetil arila | |
| MX2009013240A (es) | Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |